Precision Protein Clearance for Neurodegeneration
Neurodegenerative diseases are driven by the accumulation of toxic, aggregation-prone proteins that disrupt cellular health and lead to progressive neuronal loss. Linkage Therapeutics addresses this unmet need by engineering bifunctional intrabodies that both bind pathogenic targets and direct them to controlled proteasomal degradation.
The PTAP platform enables:
- Selective targeting of intracellular disease proteins
- Programmable and tunable protein clearance
- Ubiquitin-independent proteolysis for durable effects
- Preservation of normal protein function and proteostasis
This precision approach differentiates Linkage Therapeutics from conventional antibody and gene therapy strategies that are unable to act inside cells or modulate protein levels with the same degree of control.
